Clinical Cancer Research · 2011 · 31 citations · 36 references
MedicineMolecular BiologyOncologyCancer PharmacologyMolecular ImagingMolecular OncologyImaging BiomarkersPeptide ProdrugsProteolytic EnzymesProteolytic ProcessingTheranostic ImagingTumor ImagingMatrix Metalloproteinase ImagingMatrix Metalloproteinase-cleavable ProdrugsMatrix-assisted Laser Desorption/ionizationMatrix-assisted Laser Desorption/ionization ImagingProtease Cleavage SpecificityProtease ImagingProtease InhibitionProtease Inhibitors
PURPOSE: To develop an imaging technology for protease activities in patients that could help in prognosis prediction and in design of personalized, protease-based inhibitors and prodrugs for targeted therapy. EXPERIMENTAL DESIGN: Polyethylene glycol (PEG) was covalently attached to the N-terminus of a hydrophilic peptide substrate (GPLGVR) for matrix metalloproteinase (MMP) to increase hydrophilicity. PEG-peptide was then linked to a hydrophobic tetramethylrhodamine (TMR) domain and labeled with (18)F to form a PEG-peptide-(18)F-TMR probe. Specific cleavage of the probe by MMP2 was tested in vitro by matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF). In vivo imaging of MMP2-expressing tumors was evaluated by micro-PET. RESULTS: The hydrophobic TMR fragment (948 Da) was specifically generated by MMP2 enzymes and MMP-expressing HT1080 cells but not control MCF-7 cells. MMP-expressing HT1080 cells and tumors selectively accumulated the hydrolyzed, hydrophobic TMR fragment at sites of protease activity. Importantly, we found that (18)F-labeled probe ((18)F-TMR) preferentially localized in HT1080 tumors but not control MCF-7 tumors as shown by micro-PET. Uptake of the probe in HT1080 tumors was 18.4 ± 1.9-fold greater than in the MCF-7 tumors 30 minutes after injection. These results suggest that the PEG-peptide-(18)F-TMR probe displays high selectivity for imaging MMP activity. CONCLUSIONS: This strategy successfully images MMP expression in vivo and may be extended to other proteases to predict patient prognosis and to design personalized, protease-based inhibitors and prodrug-targeted therapies.
36
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
Amy R. Nelson, Barbara Fingleton, Mace L. Rothenberg et al. · Journal of Clinical Oncology · 2000 · 1.6K citations
Medicine, Cancer Biology, Oncology +14
Arthritis Critically Dependent on Innate Immune System Players
Hong Ji, Koichiro Ohmura, Umar Mahmood et al. · Immunity · 2002 · 694 citations · Full text
Life Sciences, Immunology, Pathology +14
Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion.
B Davies, Jonathan Waxman, Harpreet Wasan et al. · PubMed · 1993 · 427 citations
Bhaskar Kallakury, Shridevi Karikehalli, A Haholu et al. · PubMed · 2001 · 283 citations
Medicine, Cancer Biology, Oncology +15